The first cord blood transplant was performed in 1988. Since then, more than 8,000 transplants have occurred.Families know that there is only one opportunity – at birth – to collect these genetically unique stem cells and if not taken, the cord blood is simply discarded. The opportunity for expectant families to collect and store their newborn’s umbilical cord blood stem cells has only been widely available since late 1995.Currently, thousands of parents are taking advantage of this once-in-a-lifetime opportunity. Cord blood stem cells are showing significant potential to treat conditions that have no cure today – like juvenile diabetes and brain injury.
Cord Blood preservation is viewed it as a type of “biological insurance” – because these stem cells may be lifesaving to their family, as there are many dieseases cured by cord blood.Families recognize that their baby’s cord blood may offer a lifetime of protection:
- The baby’s cord blood may be used to treat nearly 80 diseases. Stem cells have been used for decades in lifesaving treatments for diseases including leukemia, other cancers, and blood disorders.
- Cord blood stem cells are showing significant potential to treat conditions that have no cure today – like juvenile diabetes and brain injury.
- The baby’s cord blood is immediately available for the family if needed, and faster treatment is always better.
- For use in regenerative medicine therapies using cord blood, the child’s own stem cells are required.
- For treating cancers and blood disorders in transplant medicine, having the family’s own cord blood available may offer significant advantages if ever needed, including fewer complications, improved survival, and a better quality of life without the need for continual anti-rejection medications.
Some families have more defined risk factors, but most families bank for the security of knowing the health benefits that stem cells may someday offer their children, themselves, or other family members.
Is Cord blood America going to be one of the hot stocks of tomorrow?
As it turns out, the Cord Blood of America been in business (Publicly traded) since 2003 and featured in countless news and media overages, including Fox news.
CBAI, moving toward achieving its goal of becoming a globally dominant stem cell storage company, recently signed a deal licensing its umbilical cord blood technology to AXM Pharma Inc., a China pharmaceutical and nutraceutical company.
Cord Blood America is located at Las Vegas and currently is the largest cryogenic storage in the world. Currently US, Russia, China, Japan, and Europe are the leaders in Cryogenic technology.
The principle of cryogenic plants operation is based on the air liquefaction and its subsequent separation with the recovery of nitrogen, oxygen, and argon.
Information from A Study of Cord Blood Banking
